BioCryst Pharmaceuticals Statistics
Total Valuation
BCRX has a market cap or net worth of $2.26 billion. The enterprise value is $2.88 billion.
Important Dates
The last earnings date was Wednesday, May 6, 2026, before market open.
| Earnings Date | May 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BCRX has 254.16 million shares outstanding. The number of shares has increased by 5.23% in one year.
| Current Share Class | 254.16M |
| Shares Outstanding | 254.16M |
| Shares Change (YoY) | +5.23% |
| Shares Change (QoQ) | +10.49% |
| Owned by Insiders (%) | 0.96% |
| Owned by Institutions (%) | 86.54% |
| Float | 220.86M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 32.95 |
| PS Ratio | 2.56 |
| Forward PS | 3.27 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 7.30 |
| P/OCF Ratio | 7.23 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 8.84, with an EV/FCF ratio of 9.29.
| EV / Earnings | n/a |
| EV / Sales | 3.26 |
| EV / EBITDA | 8.84 |
| EV / EBIT | 8.95 |
| EV / FCF | 9.29 |
Financial Position
The company has a current ratio of 1.91
| Current Ratio | 1.91 |
| Quick Ratio | 1.78 |
| Debt / Equity | n/a |
| Debt / EBITDA | 2.61 |
| Debt / FCF | 2.76 |
| Interest Coverage | 4.29 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 42.62% |
| Return on Invested Capital (ROIC) | 431.76% |
| Return on Capital Employed (ROCE) | 119.50% |
| Weighted Average Cost of Capital (WACC) | 7.25% |
| Revenue Per Employee | $2.04M |
| Profits Per Employee | -$1.05M |
| Employee Count | 435 |
| Asset Turnover | 1.87 |
| Inventory Turnover | 32.20 |
Taxes
In the past 12 months, BCRX has paid $3.81 million in taxes.
| Income Tax | 3.81M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -15.63% in the last 52 weeks. The beta is 0.57, so BCRX's price volatility has been lower than the market average.
| Beta (5Y) | 0.57 |
| 52-Week Price Change | -15.63% |
| 50-Day Moving Average | 9.18 |
| 200-Day Moving Average | 7.92 |
| Relative Strength Index (RSI) | 49.79 |
| Average Volume (20 Days) | 5,050,522 |
Short Selling Information
The latest short interest is 36.11 million, so 14.21% of the outstanding shares have been sold short.
| Short Interest | 36.11M |
| Short Previous Month | 37.42M |
| Short % of Shares Out | 14.21% |
| Short % of Float | 16.35% |
| Short Ratio (days to cover) | 7.67 |
Income Statement
In the last 12 months, BCRX had revenue of $885.72 million and -$457.98 million in losses. Loss per share was -$2.10.
| Revenue | 885.72M |
| Gross Profit | 678.70M |
| Operating Income | 322.24M |
| Pretax Income | -454.18M |
| Net Income | -457.98M |
| EBITDA | 326.46M |
| EBIT | 322.24M |
| Loss Per Share | -$2.10 |
Full Income StatementBalance Sheet
The company has $238.40 million in cash and $858.08 million in debt, with a net cash position of -$619.68 million or -$2.44 per share.
| Cash & Cash Equivalents | 238.40M |
| Total Debt | 858.08M |
| Net Cash | -619.68M |
| Net Cash Per Share | -$2.44 |
| Equity (Book Value) | -553.84M |
| Book Value Per Share | -2.18 |
| Working Capital | 178.23M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $313.10 million and capital expenditures -$2.73 million, giving a free cash flow of $310.37 million.
| Operating Cash Flow | 313.10M |
| Capital Expenditures | -2.73M |
| Depreciation & Amortization | 4.22M |
| Net Borrowing | 64.94M |
| Free Cash Flow | 310.37M |
| FCF Per Share | $1.22 |
Full Cash Flow StatementMargins
Gross margin is 76.63%, with operating and profit margins of 36.38% and -51.71%.
| Gross Margin | 76.63% |
| Operating Margin | 36.38% |
| Pretax Margin | -51.28% |
| Profit Margin | -51.71% |
| EBITDA Margin | 36.86% |
| EBIT Margin | 36.38% |
| FCF Margin | 35.04% |
Dividends & Yields
BCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.23% |
| Shareholder Yield | -5.23% |
| Earnings Yield | -20.22% |
| FCF Yield | 13.71% |
Analyst Forecast
The average price target for BCRX is $21.30, which is 139.06% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $21.30 |
| Price Target Difference | 139.06% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 8.55% |
| EPS Growth Forecast (5Y) | 17.02% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BCRX has an Altman Z-Score of -1.01 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.01 |
| Piotroski F-Score | 5 |
